Additional development and milestone payments receivable.

No definition available.

Name:	teva_AdditionalDevelopmentAndMilestonePaymentsReceivable
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate Upfront And Milestone Payments.

+ References

No definition available.

+ Details

Name:	teva_AggregateUpfrontAndMilestonePayments
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Agreement Milestone Payments

+ References

No definition available.

+ Details

Name:	teva_CollaborativeAgreementMilestonePayments
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development and launch milestone payment receivable.

+ References

No definition available.

+ Details

Name:	teva_DevelopmentAndLaunchMilestonePaymentReceivable
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Increase in development funding commitment.

+ References

No definition available.

+ Details

Name:	teva_IncreaseInDevelopmentFundingCommitment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement potential aggregate milestone payments amount.

+ References

No definition available.

+ Details

Name:	teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment.

+ References

No definition available.

+ Details

Name:	teva_MilestonePayment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payment receivable.

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentReceivable
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payment to be paid.

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentToBePaid
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payment percentage cap.

+ References

No definition available.

+ Details

Name:	teva_Milestonepaymentpercentagecap
Namespace Prefix:	teva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Phase 2b funding option amount.

+ References

No definition available.

+ Details

Name:	teva_Phase2bfundingoptionamount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Phase 3 funding option amount.

+ References

No definition available.

+ Details

Name:	teva_Phase3fundingoptionamount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Term of royalty payment.

+ References

No definition available.

+ Details

Name:	teva_TermOfRoyaltyPayment
Namespace Prefix:	teva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payments

+ References

No definition available.

+ Details

Name:	teva_UpfrontPayments
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cost of the investment.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477439/946-210-55-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 19
-Subparagraph (3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19

+ Details

Name:	us-gaap_InvestmentOwnedAtCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-3

+ Details

Name:	us-gaap_NoncashOrPartNoncashAcquisitionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-15

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-11

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 40
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481724/830-30-40-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 17A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 16
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-16

+ Details

Name:	us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481830/320-10-45-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-11

+ Details

Name:	us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=teva_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_BiolojicDesignLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	teva_StatementOfIncomeLossLocationAxis=teva_ResearchDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_RoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_TakedaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_TevasApiBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_AbingworthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_TevaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_MabxienceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_MedincellMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_ModagMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($) $ in Millions				1 Months Ended					3 Months Ended							12 Months Ended
	Jan. 11, 2026	Jul. 31, 2024	Nov. 09, 2023	Jan. 31, 2026	Jan. 31, 2024	Oct. 31, 2021	Dec. 31, 2016	Nov. 30, 2013	Dec. 31, 2025	Jun. 30, 2025	Dec. 31, 2024	Sep. 30, 2024	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 28, 2024	Oct. 03, 2023	Sep. 29, 2023
Noncash or Part Noncash Acquisitions [Line Items]
Other commitment																					$ 150
Reimbursement of research and development expenses incurred																		$ 100
Sanofi [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment									$ 250
Sanofi [Member] \| Collaborative Arrangement [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Upfront payment																$ 500		500
Milestone payment receivable																						$ 500
Development and launch milestone payment receivable																						$ 500
Biolojic Design Ltd [Member] \| Collaborative Arrangement [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Additional development and milestone payments receivable									500							500
Biolojic Design Ltd [Member] \| Research Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment					$ 10					$ 5
Royalty Pharma [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments	$ 500		$ 100
Milestone payment percentage cap	130.00%
Phase 3 funding option amount	$ 425
Phase 2b funding option amount	$ 75
Term of royalty payment			5 years
Royalty Pharma [Member] \| Research Development Expense [Member] \| Collaborative Arrangement [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Reimbursement of research and development expenses incurred																	$ 100
Takeda [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Upfront payment							$ 30
Milestone payment							$ 20							$ 25
Teva's API business [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax																8
Abingworth [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Increase in development funding commitment				$ 50
Abingworth [Member] \| Research Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Reimbursement of research and development expenses incurred																98	42
Teva [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Cost of the investment																							$ 40
Alvotech [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment									20									$ 124	$ 124	$ 124
Collaborative agreement milestone payments									$ 345
Proceeds from available for sale debt securities		$ 44
Alvotech [Member] \| Research Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment											$ 5						124
mAbxience [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments																291
mAbxience [Member] \| Research Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																$ 29
Aggregate upfront and milestone payments											$ 15						$ 20
MedinCell [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment													$ 3
Collaborative agreement milestone payments								$ 105				$ 112
MedinCell [Member] \| Research Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment													$ 5
MODAG [Member]
Noncash or Part Noncash Acquisitions [Line Items]
License agreement potential aggregate milestone payments amount						$ 20
MODAG [Member] \| Research Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment															$ 10
Milestone Payment To Be Paid										$ 10